444,132 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Bought by Marshall Wace LLP

Marshall Wace LLP acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 444,132 shares of the biopharmaceutical company’s stock, valued at approximately $4,636,000. Marshall Wace LLP owned approximately 0.35% of Dynavax Technologies as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Advisors Asset Management Inc. raised its position in Dynavax Technologies by 498.0% during the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 1,967 shares in the last quarter. Quantbot Technologies LP grew its position in shares of Dynavax Technologies by 940.7% in the first quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 2,267 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in Dynavax Technologies by 1,875.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 7,900 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 7,500 shares in the last quarter. KBC Group NV acquired a new stake in shares of Dynavax Technologies during the third quarter worth $100,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Dynavax Technologies in the first quarter valued at about $102,000. Institutional investors and hedge funds own 94.26% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DVAX. HC Wainwright lowered their target price on shares of Dynavax Technologies from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, February 24th. JMP Securities increased their target price on Dynavax Technologies from $22.00 to $25.00 and gave the company a “market outperform” rating in a research report on Friday, February 24th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.33.

Insider Activity

In other news, CAO Justin Burgess sold 22,371 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $10.38, for a total transaction of $232,210.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.31% of the stock is currently owned by corporate insiders.

Dynavax Technologies Trading Up 0.3 %

DVAX opened at $9.76 on Tuesday. The firm has a market capitalization of $1.25 billion, a PE ratio of 4.95 and a beta of 1.45. The company has a debt-to-equity ratio of 0.38, a current ratio of 6.11 and a quick ratio of 5.71. Dynavax Technologies Co. has a fifty-two week low of $7.26 and a fifty-two week high of $17.48. The company’s 50-day moving average is $10.95 and its 200 day moving average is $11.25.

About Dynavax Technologies

(Get Rating)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.